Micronucleus test of mofezolac (N-22).
A micronucleus test using BDF1 male mice was conducted in order to evaluate the in vivo mutagenicity of mofezolac (N-22). N-22 was orally administered at doses of 75, 150, 300 and 600 mg/kg, with a sampling time of 24 hr. The frequency of polychromatic erythrocytes with micronuclei was 0.07-0.08% in the groups treated with N-22 and did not differ markedly from that of the vehicle control (0.13%). The present study indicates that N-22 has no in vivo mutagenic properties.
Ohuchida
A
A
Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Furukawa
A
A
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D004913:Erythrocytes, Abnormal / Q000187:drug effects / Q000473:pathology; D007555:Isoxazoles / Q000633:toxicity*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects / Q000473:pathology; D015162:Micronucleus Tests / Q000379:methods; D016296:Mutagenesis / Q000187:drug effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007555:Isoxazoles; C054999:mofezolac